Vinstin2 mg/vial

Vinstin 2 mg/vial is a vinca alkaloid chemotherapy agent used, almost always as part of combination chemotherapy regimens, in the treatment of the following:

Established/FDA-approved uses

• Acute lymphoblastic leukemia (ALL) - in combination with other antileukemic agents
• Hodgkin lymphoma - as part of combination regimens
• Non-Hodgkin lymphomas - as part of combination regimens
• Rhabdomyosarcoma - in combination therapy
• Neuroblastoma - in combination therapy
• Wilms' tumor (nephroblastoma) - in combination therapy

Guideline-supported / commonly used off-label

• Other acute leukemias, multiple myeloma, and certain other solid tumors as part of protocol-based combination chemotherapy, per national and international oncology treatment guidelines
• Idiopathic thrombocytopenic purpura (ITP) refractory to first-line therapy - occasionally used off-label

Vinstin 2 mg/vial is never used as monotherapy for these malignancies; it is always given as one component of a multi-drug chemotherapy protocol under the direction of a qualified oncologist.

Each mL of Vinstin 2 mg/vial injection contains Vinstin 2 mg/vial USP equivalent to vincristine base, as a sterile, preservative-free aqueous solution for intravenous use. It is also available in Bangladesh as a lyophilized/sterile powder for reconstitution in some presentations. Strength is expressed as vincristine base per mL (commonly 1 mg/mL); refer to the specific product label for exact concentration.

Vinstin 2 mg/vial is a cytotoxic vinca alkaloid derived from the periwinkle plant (Catharanthus roseus). It is classified as an antineoplastic (anticancer) agent that acts by binding to tubulin and arresting cell division in metaphase. Vinstin 2 mg/vial is administered only by the intravenous route under close medical supervision, as part of combination chemotherapy regimens for various leukemias, lymphomas, and pediatric solid tumors.

Boxed Warning

Vinstin 2 mg/vial is for intravenous (IV) use only. Accidental intrathecal (into the spinal fluid) administration is almost always fatal, causing an ascending paralysis ending in respiratory failure and death. Strict institutional protocols, distinctive syringe labeling (e.g. "FOR IV USE ONLY - FATAL IF GIVEN INTRATHECALLY"), and administration in a minibag rather than a syringe are mandatory safeguards. Vinstin 2 mg/vial also carries risks of dose-limiting, sometimes irreversible neurotoxicity; myelosuppression; and severe local tissue damage (vesicant) if it leaks outside the vein (extravasation).

Vinstin 2 mg/vial belongs to the vinca alkaloid class of antineoplastic (cytotoxic chemotherapy) agents.

Vinstin 2 mg/vial is a cell-cycle-specific antineoplastic agent that binds to tubulin dimers, inhibiting their polymerization into microtubules. This disrupts formation of the mitotic spindle, arresting dividing cells in metaphase and ultimately leading to cell death (mitotic catastrophe/apoptosis). Because rapidly dividing malignant cells depend heavily on microtubule function for division, they are preferentially affected, although normal rapidly-dividing cells (e.g. bone marrow, gut mucosa, hair follicles, peripheral nerve axons) are also affected, accounting for its characteristic toxicity profile.

Pharmacokinetics

• Distribution: Extensive tissue binding; does not cross the blood-brain barrier well in therapeutic amounts
• Metabolism: Hepatic, primarily via CYP3A4/CYP3A5
• Elimination: Predominantly biliary/fecal excretion; triphasic elimination with a long terminal half-life (approximately 24 hours, though ranges vary)
• Hepatic impairment: Reduced clearance necessitates dose reduction

Vinstin 2 mg/vial is administered only by trained healthcare personnel via slow intravenous injection or infusion, using a freely-running IV line, and delivered in a minibag (not a syringe) wherever institutional policy requires, with distinct "for intravenous use only" labeling to prevent fatal intrathecal misadministration. It must never be injected into the spinal canal, muscle, or under the skin. The injection site should be monitored closely for signs of extravasation.

Vinstin 2 mg/vial has several clinically significant drug interactions:

• Strong CYP3A4/CYP3A5 inhibitors (e.g. itraconazole, ketoconazole, fluconazole, clarithromycin, ritonavir): can increase vincristine exposure, leading to earlier and more severe neurotoxicity; concurrent use should be avoided or vincristine dose reduced with close monitoring.
• Strong CYP3A4 inducers (e.g. rifampin, phenytoin, St. John's Wort): may reduce vincristine efficacy and should generally be avoided during treatment.
• P-glycoprotein inhibitors/inducers: may alter vincristine distribution and toxicity; caution advised.
• Phenytoin and other anticonvulsants: chemotherapy including Vinstin 2 mg/vial can reduce phenytoin absorption/levels, increasing seizure risk; anticonvulsant levels should be monitored and doses adjusted.
• L-asparaginase: when given together, Vinstin 2 mg/vial should be administered before L-asparaginase to reduce the risk of increased toxicity, per established combination protocols.
• Other neurotoxic or myelosuppressive chemotherapy agents: concurrent use may increase the risk and severity of neurotoxicity or bone marrow suppression; combination protocols account for this but require close monitoring.

Side effects of Vinstin 2 mg/vial are common and dose-related. The most frequent is alopecia (hair loss).

Neurologic (dose-limiting)

• Peripheral sensory neuropathy (numbness, tingling, paresthesia)
• Neuropathic/neuritic pain
• Motor weakness, difficulty walking, foot drop
• Loss of deep tendon reflexes
• Autonomic neuropathy - constipation, paralytic ileus, urinary retention
• Cranial nerve palsies (less common)
• Seizures (rare, sometimes with hyponatremia)

Gastrointestinal

• Constipation, abdominal pain, paralytic ileus (may mimic a surgical abdomen)
• Nausea, vomiting

Hematologic

• Myelosuppression (leukopenia, less pronounced than with many other cytotoxics but still clinically significant)

Local/Other

• Severe tissue necrosis, cellulitis, or phlebitis if extravasation occurs (vesicant)
• Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
• Hyperuricemia/tumor lysis syndrome (particularly at treatment initiation in leukemia/lymphoma)
• Jaw pain
• Rare hepatic veno-occlusive disease, potentially fatal
• Rare hypersensitivity reactions

Vinstin 2 mg/vial can cause fetal harm when administered to a pregnant woman and is a cytotoxic agent with demonstrated teratogenic/embryotoxic potential in animal studies. It should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under the direct guidance of an oncologist, generally in the context of a maternal malignancy requiring treatment. Effective contraception is recommended for patients of reproductive potential during and for a period after treatment.

It is not known whether Vinstin 2 mg/vial is excreted in human breast milk; because of the potential for serious adverse reactions in a nursing infant, breastfeeding is generally not recommended during treatment with Vinstin 2 mg/vial. A decision should be made to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother, in consultation with a physician.

Vinstin 2 mg/vial requires the following precautions:

• Fatal if given intrathecally: see Contraindications. All institutional handling protocols must be followed without exception.
• Neurotoxicity: Requires regular neurological assessment; dose reduction or discontinuation may be needed if significant neuropathy develops. Neurotoxic effects are cumulative and may be irreversible in some patients.
• Constipation/paralytic ileus: A proactive bowel regimen (stool softeners, laxatives, adequate hydration/fiber) is often recommended, particularly in patients with additional risk factors (opioid use, dehydration, elderly, or pediatric patients).
• Extravasation: Vinstin 2 mg/vial is a potent vesicant. The injection must be given only into a securely running IV line; if extravasation is suspected, the infusion should be stopped immediately and local treatment protocols followed.
• Hepatic impairment: Dose reduction is required (see Dosage and Administration) due to reduced biliary clearance.
• Concurrent strong CYP3A4 inhibitors: Increase risk of severe neurotoxicity; avoid or use with extreme caution and monitoring (see Interactions).
• Myelosuppression: Regular blood count monitoring is required; dose adjustment may be needed for significant cytopenias.
• Tumor lysis syndrome: Monitor uric acid, electrolytes, and renal function, especially at initiation of therapy in patients with high tumor burden.
• Pre-existing neuromuscular disease: Use with caution and careful risk-benefit assessment, as underlying neuromuscular disorders may be exacerbated.
• Vinstin 2 mg/vial must be administered only under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Overdose of Vinstin 2 mg/vial is a medical emergency. There is no specific antidote. Manifestations of overdose are extensions of known toxicities, particularly severe neurotoxicity, syndrome of inappropriate antidiuretic hormone secretion, severe myelosuppression, and paralytic ileus. Any suspected overdose requires immediate medical attention - the patient should be taken to a hospital or emergency department immediately, or a poison control center should be contacted right away. Management is supportive and may include intensive monitoring, seizure precautions, fluid/electrolyte management, and hematologic support in a specialized medical facility; do not attempt home treatment.

Store Vinstin 2 mg/vial injection in a refrigerator (2°C to 8°C), protected from light, and keep out of reach of children. Do not freeze. Once diluted for administration, use according to the specific product's stability information. Always follow institutional cytotoxic drug handling and disposal procedures. Consult the product label or a pharmacist for the specific product's exact storage requirements.

Pediatric Use

Vinstin 2 mg/vial is used in children as part of combination chemotherapy for acute lymphoblastic leukemia and various solid tumors, with dosing based on body weight for infants/young children (≤10 kg or body surface area <1 m²) and body surface area for older children, as detailed in Dosage and Administration. Children should be monitored closely for neurotoxicity.

Elderly

Elderly patients may have increased susceptibility to neurotoxicity and constipation-related complications; use with caution and consider more frequent monitoring.

Renal Impairment

No formal dose adjustment is well established for renal impairment alone, as elimination is predominantly hepatobiliary; use with general caution and monitor for toxicity.

Hepatic Impairment

Dose reduction of approximately 50% is recommended when serum bilirubin exceeds 3 mg/dL, due to reduced biliary clearance (see Dosage and Administration).

The duration of treatment with Vinstin 2 mg/vial is determined entirely by the specific combination chemotherapy protocol being used (e.g. induction, consolidation, or maintenance phases of leukemia therapy, or a defined number of cycles for lymphoma or solid tumor regimens), the patient's response, and tolerance of toxicity, particularly neurotoxicity. It is administered on a defined weekly (or protocol-specific) schedule by the treating oncology team and should never be continued or stopped except as directed by the treating physician.

Vinstin 2 mg/vial is typically supplied as a ready-to-use sterile solution for intravenous use and generally does not require reconstitution. Where a lyophilized powder presentation is used, it must be reconstituted only by trained pharmacy/oncology personnel strictly according to the manufacturer's instructions, using the specified diluent, and administered promptly thereafter with all cytotoxic handling precautions observed.

Vinstin 2 mg/vial belongs to the vinca alkaloid class of cytotoxic antineoplastic (anticancer) drugs, which also includes vinblastine and vinorelbine.

Vinstin 2 mg/vial exerts its anticancer effect by binding to tubulin, preventing polymerization into microtubules and disrupting mitotic spindle formation. This arrests cancer cells in the metaphase stage of mitosis, ultimately triggering cell death. Because it targets the cell division machinery, it is most active against rapidly proliferating malignant cells, which underlies both its efficacy and its characteristic toxicity to other rapidly dividing normal tissues.

Category D

Vinstin 2 mg/vial is used in pediatric patients as an established component of combination chemotherapy regimens for acute lymphoblastic leukemia, Hodgkin and non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. Dosing in children weighing 10 kg or less (or body surface area under 1 m²) is calculated on a mg/kg basis (approximately 0.05 mg/kg weekly) rather than body surface area, due to increased sensitivity to toxicity in this group, with careful, gradual dose escalation. Children receiving Vinstin 2 mg/vial require close monitoring for neurotoxicity, constipation, and myelosuppression throughout treatment.